Related references
Note: Only part of the references are listed.Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes
Rajendra Karki et al.
CELL (2021)
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
Yang Cao et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Tocilizumab treatment in COVID-19: A single center experience
Pan Luo et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Robert Zeiser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation
Lauren K. Meyer et al.
BLOOD (2020)
Cytokine Storms: Understanding COVID-19
Nilam Mangalmurti et al.
IMMUNITY (2020)
Small Intestinal Immunopathology Plays a Big Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-γ, IL-17A, and a Janus Kinase Inhibitor
Shiv D. Kale et al.
FRONTIERS IN IMMUNOLOGY (2020)
Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol
Enrico Capochiani et al.
FRONTIERS IN MEDICINE (2020)
Interleukin-6 Blocking vs. JAK-STAT Inhibition for Prevention of Lung Injury in Patients with COVID-19
Joseph Meletiadis et al.
INFECTIOUS DISEASES AND THERAPY (2020)
Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy
Eduardo Huarte et al.
CLINICAL CANCER RESEARCH (2020)
Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment
Swamy Yeleswaram et al.
CLINICAL IMMUNOLOGY (2020)
Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis
Li Jianguo et al.
PEDIATRICS (2020)
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
Alessandro Gozzetti et al.
LEUKEMIA (2020)
An inflammatory cytokine signature predicts COVID-19 severity and survival
Diane Marie Del Valle et al.
NATURE MEDICINE (2020)
Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome
Puja Mehta et al.
LANCET RHEUMATOLOGY (2020)
IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
Etienne Dufranc et al.
CRITICAL CARE (2020)
Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis
Sabrin Albeituni et al.
BLOOD (2019)
Targeting the Janus Kinase Family in Autoimmune Skin Diseases
Michael D. Howell et al.
FRONTIERS IN IMMUNOLOGY (2019)
The Immunology of Macrophage Activation Syndrome
Courtney B. Crayne et al.
FRONTIERS IN IMMUNOLOGY (2019)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Srdan Verstovsek et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era
Edward M. Behrens et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis
Rupali Das et al.
BLOOD (2016)
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
Silvia Spoerl et al.
BLOOD (2014)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
Alfonso Quintas-Cardama et al.
BLOOD (2010)
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
Norihiro Nishimoto et al.
BLOOD (2008)
Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester
Ben J. C. Quah et al.
NATURE PROTOCOLS (2007)
Share Paper
